IL274198B2 - Use of Nox inhibitors to treat cancer - Google Patents

Use of Nox inhibitors to treat cancer

Info

Publication number
IL274198B2
IL274198B2 IL274198A IL27419820A IL274198B2 IL 274198 B2 IL274198 B2 IL 274198B2 IL 274198 A IL274198 A IL 274198A IL 27419820 A IL27419820 A IL 27419820A IL 274198 B2 IL274198 B2 IL 274198B2
Authority
IL
Israel
Prior art keywords
optionally substituted
alkyl
methyl
inhibitor
amino
Prior art date
Application number
IL274198A
Other languages
English (en)
Hebrew (he)
Other versions
IL274198A (en
IL274198B1 (en
Original Assignee
Calliditas Therapeutics Suisse Sa
Univ Southampton
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Calliditas Therapeutics Suisse Sa, Univ Southampton filed Critical Calliditas Therapeutics Suisse Sa
Publication of IL274198A publication Critical patent/IL274198A/en
Publication of IL274198B1 publication Critical patent/IL274198B1/en
Publication of IL274198B2 publication Critical patent/IL274198B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/58—Prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL274198A 2017-11-01 2020-04-23 Use of Nox inhibitors to treat cancer IL274198B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17199601.0A EP3479843A1 (en) 2017-11-01 2017-11-01 Use of nox inhibitors for treatment of cancer
PCT/EP2018/079945 WO2019086579A1 (en) 2017-11-01 2018-11-01 Use of nox inhibitors for treatment of cancer

Publications (3)

Publication Number Publication Date
IL274198A IL274198A (en) 2020-05-31
IL274198B1 IL274198B1 (en) 2023-03-01
IL274198B2 true IL274198B2 (en) 2023-07-01

Family

ID=60201917

Family Applications (1)

Application Number Title Priority Date Filing Date
IL274198A IL274198B2 (en) 2017-11-01 2020-04-23 Use of Nox inhibitors to treat cancer

Country Status (15)

Country Link
US (2) US12011436B2 (cg-RX-API-DMAC7.html)
EP (2) EP3479843A1 (cg-RX-API-DMAC7.html)
JP (2) JP7849141B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250086790A (cg-RX-API-DMAC7.html)
CN (1) CN111344013A (cg-RX-API-DMAC7.html)
AU (1) AU2018359634B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020008440A2 (cg-RX-API-DMAC7.html)
CA (1) CA3079991A1 (cg-RX-API-DMAC7.html)
DK (1) DK3703747T3 (cg-RX-API-DMAC7.html)
ES (1) ES3054839T3 (cg-RX-API-DMAC7.html)
FI (1) FI3703747T3 (cg-RX-API-DMAC7.html)
IL (1) IL274198B2 (cg-RX-API-DMAC7.html)
MX (1) MX2020004376A (cg-RX-API-DMAC7.html)
PT (1) PT3703747T (cg-RX-API-DMAC7.html)
WO (1) WO2019086579A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3628669A1 (en) 2018-09-28 2020-04-01 GenKyoTex Suisse SA Novel compounds as nadph oxidase inhibitors
EP3946297A4 (en) * 2019-04-01 2023-08-02 Emory University HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASE INHIBITORS AND THEIR USES IN THE TREATMENT OF CANCER
PH12022551379A1 (en) 2019-12-06 2023-05-03 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
SI4347031T1 (sl) 2021-06-04 2026-01-30 Vertex Pharmaceuticals Incorporated N-(hidroksialkil (hetero)aril) tetrahidrofuran karboksamidi kot modulatorji natrijevih kanalčkov
US11896719B2 (en) 2022-01-24 2024-02-13 Calliditas Therapeutics Ab Pharmaceutical compositions
CN119096936A (zh) * 2024-08-28 2024-12-10 南方医科大学第三附属医院(广东省骨科研究院) 一种胆管癌足垫腘窝淋巴结自发转移动物模型的构建方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2165707A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3931407A (en) 1973-03-01 1976-01-06 American Hoechst Corporation Method of treatment with and compositions containing condensed pyrroles bearing an N-phenyl substituent
DE3728278A1 (de) 1986-12-17 1988-06-23 Bayer Ag Herbizide und fungizide mittel auf basis von substituierten pyrazolin-5-on derivaten
DE19518082A1 (de) 1995-05-17 1996-11-21 Merck Patent Gmbh 4(-Arylaminomethylen)-2,4-dihydropyrazol-3-one
US5763496A (en) 1995-11-27 1998-06-09 The Research Foundation Of State University Of New York Prevention of atherosclerosis using NADPH oxidase inhibitors
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
WO1998037068A1 (en) 1997-02-21 1998-08-27 Bristol-Myers Squibb Company Benzoic acid derivatives and related compounds as antiarrhythmic agents
IL144468A0 (en) 2000-07-27 2002-05-23 Pfizer Prod Inc Use of growth hormone secretagogues for improvement of functional health status
US7902179B2 (en) 2001-04-26 2011-03-08 Ajinomoto Co., Inc. Heterocyclic compounds
EP1291017A3 (en) 2001-09-10 2003-07-02 Warner-Lambert Company Use of statins to inhibit formation of osteoclasts
CA2483306A1 (en) 2002-04-23 2003-11-06 Shionogi & Co., Ltd. Pyrazolo[1,5-a]pyrimidine derivative and nad(p)h oxidase inhibitor containing the same
WO2004005267A2 (en) 2002-07-03 2004-01-15 Janssen Pharmaceutica, N.V. Heteroaryl compounds useful in treating inflammatory disorders
CN1774243A (zh) 2003-02-28 2006-05-17 霍华德弗洛里实验生理及医药学院 治疗组合物
EP1616576A4 (en) 2003-04-08 2010-02-10 Mitsubishi Tanabe Pharma Corp SPECIFIC NAD (P) H OXIDASE HEMMER
WO2005080378A1 (ja) 2004-02-24 2005-09-01 Mitsubishi Pharma Corporation 縮合ピリダジン誘導体
WO2006041874A2 (en) 2004-10-04 2006-04-20 Myriad Genetics, Inc. Compounds for alzheimer's disease
FR2882654B1 (fr) 2005-03-01 2007-04-27 Servier Lab Utilisation de derives de la diosmetine pour le traitement et la prevention des pathologies thrombotiques
US7759337B2 (en) 2005-03-03 2010-07-20 Amgen Inc. Phthalazine compounds and methods of use
EP1896134A2 (en) 2005-06-13 2008-03-12 Rigel Pharmaceuticals, Inc. Methods and compositions for treating degenerative bone disorders
US20070014739A1 (en) 2005-07-14 2007-01-18 Eldridge Gary R Compositions and methods for controlling biofilms and bacterial infections
DE102005048897A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
JP2009532501A (ja) 2006-04-04 2009-09-10 ミリアド ジェネティクス, インコーポレイテッド 疾患および障害のための化合物
WO2008030887A2 (en) 2006-09-05 2008-03-13 Bipar Sciences, Inc. Methods for designing parp inhibitors and uses thereof
US8709434B2 (en) 2006-11-13 2014-04-29 Pcb Associates, Inc. Compositions for inhibiting NADPH oxidase activity
US9284355B2 (en) * 2006-12-28 2016-03-15 The Trustees Of The University Of Pennsylvania Herpes simplex virus combined subunit vaccines and methods of use thereof
EP2002835A1 (en) 2007-06-04 2008-12-17 GenKyo Tex Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2000176A1 (en) 2007-06-04 2008-12-10 GenKyo Tex Tetrahydroindole derivatives as NADPH Oxidase inhibitors
WO2009072643A1 (en) 2007-12-03 2009-06-11 Takeda Pharmaceutical Company Limited Nitrogen-containing heterocyclic compound and use thereof
US20090163452A1 (en) 2007-12-20 2009-06-25 Schwartz Janice B Compositions and methods for lowering serum cholesterol
FR2929276B1 (fr) 2008-04-01 2010-04-23 Servier Lab Nouveaux derives de diosmetine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
EP2166009A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as nadph oxidase inhibitors
EP2166008A1 (en) 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2305679A1 (en) * 2009-09-28 2011-04-06 GenKyoTex SA Pyrazoline dione derivatives as nadph oxidase inhibitors
WO2011085293A1 (en) 2010-01-08 2011-07-14 Beth Israel Deaconess Medical Center Methods and compositions for the treatment of migraine headaches
EP2361912A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2361911A1 (en) 2010-02-18 2011-08-31 GenKyoTex SA Pyrazolo piperidine derivatives as NADPH oxidase inhibitors
EP2704709B1 (en) 2011-05-02 2020-09-02 Altaba, Ariel Ruiz Macrocyclic lactones and use thereof
EP2591782A1 (en) 2011-11-11 2013-05-15 Johann Wolfgang Goethe-Universität Nadph oxidase 4 inhibitors and use thereof
EP2857399A1 (en) 2013-10-03 2015-04-08 GenKyoTex SA Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction
EP3034500A1 (en) 2014-12-17 2016-06-22 Genkyotex Sa Amido thiazole derivatives as NADPH oxidase inhibitors
CN107743483B (zh) 2015-06-22 2022-01-28 埃科特莱茵药品有限公司 Nadph氧化酶4抑制剂

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2165707A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors
EP2166010A1 (en) * 2008-09-23 2010-03-24 Genkyo Tex Sa Pyrazolo pyridine derivatives as NADPH oxidase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BALAR ARJUN VASANT ET AL:, PD-1 AND PD-L1 ANTIBODIES IN CANCER: CURRENT STATUS AND FUTURE DIRECTIONS, 17 February 2017 (2017-02-17) *
CHAOFEI CHEN:, THE ROLE OF NOX4 AND TRX2 IN ANGIOGENESIS AND THEIR POTENTIAL CROSS-TALK, 8 June 2017 (2017-06-08) *
CHRISTOPHER J HANLEY ET AL:, TARGETING THE MYOFIBROBLASTIC CANCER-ASSOCIATED FIBROBLAST PHENOTYPE THROUGH INHIBITION OF N0X4, 3 August 2017 (2017-08-03) *
G TEIXEIRA:, THERAPEUTIC POTENTIAL OF NADPH OXIDASE 1/4 INHIBITORS, 7 June 2016 (2016-06-07) *

Also Published As

Publication number Publication date
US20240358687A1 (en) 2024-10-31
AU2018359634A1 (en) 2020-05-21
RU2020115807A3 (cg-RX-API-DMAC7.html) 2022-02-16
DK3703747T3 (en) 2025-12-01
EP3703747A1 (en) 2020-09-09
PT3703747T (pt) 2025-12-05
BR112020008440A2 (pt) 2020-10-06
IL274198A (en) 2020-05-31
KR20250086790A (ko) 2025-06-13
US12011436B2 (en) 2024-06-18
IL274198B1 (en) 2023-03-01
MX2020004376A (es) 2020-12-03
EP3479843A1 (en) 2019-05-08
AU2018359634B2 (en) 2025-07-24
KR20200079265A (ko) 2020-07-02
US20210177811A1 (en) 2021-06-17
ES3054839T3 (en) 2026-02-06
JP2021501216A (ja) 2021-01-14
JP2023162250A (ja) 2023-11-08
CA3079991A1 (en) 2019-05-09
RU2020115807A (ru) 2021-11-15
CN111344013A (zh) 2020-06-26
JP7849141B2 (ja) 2026-04-21
EP3703747B1 (en) 2025-09-03
WO2019086579A1 (en) 2019-05-09
FI3703747T3 (fi) 2025-12-04

Similar Documents

Publication Publication Date Title
IL274198B1 (en) Use of Nox inhibitors to treat cancer
AU2020274011B2 (en) Heteroarylaminopyrimidine amide autophagy inhibitors and methods of use thereof
JP6133291B2 (ja) ピラゾロ[3,4−c]ピリジン化合物と使用方法
ES2540996T3 (es) Compuestos de N-(1H-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida sustituidos como inhibidores de tirosina cinasa del receptor de tipo III
KR101985984B1 (ko) 키나아제 저해제로서의 벤조니트릴 유도체
KR20210103498A (ko) 메티오닌 아데노실트랜스퍼라제 2a 억제제로서 2-옥소퀴나졸린 유도체
RU2013124101A (ru) Гетероциклические амины и их применения
KR20210100155A (ko) Ret 억제제, 이의 약학 조성물 및 용도
US9181272B2 (en) Aldosterone synthase inhibitors
JP2021501216A5 (cg-RX-API-DMAC7.html)
RU2009125897A (ru) Ингибиторы фосфоинозитид-3-киназы и способы их применения
KR20150020228A (ko) 아미노퀴나졸린 및 피리도피리미딘 유도체
JP2010512338A5 (cg-RX-API-DMAC7.html)
AU2019249849A1 (en) BRM targeting compounds and associated methods of use
BRPI0821994A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, e, uso de um composto
AU2009227013A1 (en) Novel heterocyclic compounds and uses therof
EP2146716A1 (en) Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases
JP2013544256A5 (cg-RX-API-DMAC7.html)
EP3197884A1 (en) Aminotriazine derivatives useful as tank-binding kinase inhibitor compounds
JP2012525367A5 (cg-RX-API-DMAC7.html)
KR20250021398A (ko) Kif18a 저해용 화합물
CN120225521A (zh) Akt1调节剂
CA3190441A1 (en) Protein secretion inhibitors
RU2022107496A (ru) Производные гетероциклического пиразола как ингибиторы рецепторной тирозикиназы типа III
WO2024226875A2 (en) Compounds, compositions and methods for attenuation of mammalian translation of c-myc or n-myc proteins of the myc proto-oncogene family of bhlh transcription factors